Search results for "Colitis"

showing 10 items of 483 documents

HLA antigens in ulcerative colitis: a study in the Sicilian population

2008

HLA antigens were investigated in 41 Sicilian patients with ulcerative colitis and in 151 healthy controls. Frequencies of HLA-B5 and DR2 were increased in the group of patients with ulcerative colitis whereas the DR3 antigen frequency was decreased. However the corrected p values were not significant. Thus, present results indicate that in ulcerative colitis HLA linked genetic factors play a marginal role, if any.

education.field_of_studybusiness.industryImmunologyPopulationGeneral MedicineHuman leukocyte antigenmedicine.diseaseBiochemistryUlcerative colitisGene FrequencyItalyAntigenHLA AntigensImmunologyGeneticsHumansImmunology and AllergyMedicineColitis UlcerativeeducationbusinessTissue Antigens
researchProduct

Interés de los índices clínicos en el tratamiento quirúrgico de la enterocolitis necrotizante

2015

INTRODUCCIÓN: Uno de los retos fundamentales de la terapia quirúrgica de los neonatos con enterocolitis necrotizante es decidir el momento adecuado para la intervención. Los índices clínicos pueden mejorar el proceso de toma de decisiones en beneficio del paciente: el MDAS (Metabolic Derangement Acuity Score) y el SNAPPE-II (Score for Neonatal Acute Physiology Perinatal Extension-II) son dos índices clínicos que fueron propuestos como buenas pruebas para decir qué pacientes con enterocolitis necrotizante necesitaban tratamiento quirúrgico; no obstante, su rendimiento diagnóstico como predictores de dicho tratamiento quirúrgico no fue calculado. El objetivo de esta investigación fue obtener …

enterocolitis necrotizanteUNESCO::CIENCIAS MÉDICAS ::Ciencias clínicas::Pediatríacurva ROC:CIENCIAS MÉDICAS ::Ciencias clínicas::Pediatría [UNESCO]índice de severidad de la enfermedad:CIENCIAS MÉDICAS ::Cirugía [UNESCO]cirugíaneonatologíaUNESCO::CIENCIAS MÉDICAS ::Cirugía
researchProduct

Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis

2020

Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission are evaluated. Finally, a series of recommendations addressed to patients are giv…

glucocorticoidesmedicine.medical_specialtycolitisAdministration TopicalhumanosAnti-Inflammatory AgentsTopical treatmentmesalamina03 medical and health scienceschemistry.chemical_compound0302 clinical medicineMesalazineTopical treatmentmedicineMesalazinaHumansCorticosteroidsMesalamineGlucocorticoidsCrohn's diseasebusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseantiinflamatoriosUlcerative colitisDermatologyClinical PracticechemistryUlcerative colitis030220 oncology & carcinogenesisDisease remission030211 gastroenterology & hepatologyColitis UlcerativeMesalazinebusiness
researchProduct

HLA-DQ de enfermedad celíaca en pacientes con enfermedad inflamatoria intestinal crónica

2015

Introducción: La enfermedad celíaca (EC) y la Enfermedad Inflamatoria Intestinal Crónica (EIIC, que incluye CU –colitis ulcerosa- y ECr –Enfermedad de Crohn-) son enfermedades cuya incidencia y prevalencia va en aumento, y en las que se consideraba que tener una de ellas aumentaba la predisposición a la otra. El HLA-DQ 2 y DQ8, de riesgo de EC (HLA-EC), tiene un alto valor predictivo negativo, estando presente en el 95-99% de los celíacos. Nuestra hipótesis era que el HLA-EC no es más frecuente en la EIIC. Material y método: Se incluyeron prospectivamente pacientes adultos con EIIC, de origen caucásico, de nuestra Unidad de EIIC. Se les realizaba entrevista, estudio de su historia clínica y…

hlaUNESCO::CIENCIAS MÉDICAS ::Medicina interna::Gastroenterologíaenfermedad de Crohn:CIENCIAS MÉDICAS ::Medicina interna::Gastroenterología [UNESCO]celiaquíacolitis ulcerosa
researchProduct

Telemedicine Is an Effective Tool to Monitor Disease Activity in IBD Patients in the COVID-19 Era: A Single Centre Experience Based on Objective Data

2022

Background: The COVID-19 outbreak has led IBD clinics to adopt a remote monitoring approach in order to guarantee an adequate follow-up of patients with inflammatory bowel disease (IBD) and ensure the rules of social distancing. Aim: The aim of the study was to perform a survey on IBD patients who underwent remote monitoring in our tertiary referral center, to assess adherence, patients’ perceptions and satisfaction, and finally their opinions for future monitoring. Furthermore, we evaluated changes in disease activity and Quality of Life (QoL) using validated questionnaires. Methods: Consecutive patients with IBD scheduled for follow-up visits were switched to remote monitoring throu…

inflammatory bowel disease; COVID-19; telemedicine; ulcerative colitis; Crohn’s DiseaseHepatologyinflammatory bowel diseaseGastroenterologyCrohn's Disease.COVID-19telemedicineulcerative coliti
researchProduct

Cyclosporine or infliximab as rescue therapy in severe 2 refractory ulcerative colitis: Early and long-term data 3 from a retrospective observational…

2012

Introduction: About 30–40% of patients with acute severe ulcerative colitis (UC) fail to respond 23 to intensive intravenous (iv) corticosteroid treatment. Iv cyclosporine and infliximab are an ef- 24 fective rescue therapy in steroid-refractory UC patients but up to now it is still unclear which is Q225 the best therapeutic choice in this setting of patients. 26 Methods: We reviewed our series of severe steroid-refractory colitis admitted consecutively in 27 our referral center since 1994 comparing two historical cohort treated with cyclosporine or 28 infliximab. Iv cyclosporine was administered at the dosage of 2 mg/kg and infliximab at the dos- 29 age of 5 mg/kg. The main outcome was the…

infliximabulcerative colitiscyclosporine
researchProduct

INFLIXIMAB FOR PEDIATRIC ULCERATIVE COLITIS:A RETROSPECTIVE ITALIAN MULTICENTER STUDY

2008

. Dig Liver Dis. 2008 Jul;40 Suppl 2:S260-4. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, de'Angelis GL, Federici T. Division Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Rome "La Sapienza", Rome, Italy. salvatore.cucchiara@uniroma1.it BACKGROUND: Infliximab (IFX), the chimeric anti TNFalpha antibody, an established treatment for Crohn's disease in adults and in children, is used less frequently in ulcerative colitis (UC). AIM OF THE STUDY: To report the clinical course of pediatric patients with active UC receiving IFX. PATIENTS AND…

infliximab.ulcerative colitis.
researchProduct

The Administration of Escherichia coli Nissle 1917 Ameliorates Development of DSS-Induced Colitis in Mice

2018

The beneficial effects of probiotics on immune-based pathologies such as inflammatory bowel disease (IBD) have been well reported. However, their exact mechanisms have not been fully elucidated. Few studies have focused on the impact of probiotics on the composition of the colonic microbiota. The aim of the present study was to correlate the intestinal anti-inflammatory activity of the probiotic Escherichia coli Nissle 1917 (EcN) in the dextran sodium sulfate (DSS) model of mouse colitis with the changes induced in colonic microbiota populations. EcN prevented the DSSinduced colonic damage, as evidenced by lower disease activity index (DAI) values and colonic weight/length ratio, when compa…

intestinal microbiota0301 basic medicineDSS colitisIntestinal microbiotaProbioticmedicine.disease_causeInflammatory bowel diseaselaw.invention03 medical and health sciencesProbioticImmune systemlawmicroRNAmedicinePharmacology (medical)ColitisEscherichia coliOriginal ResearchPharmacologymicroRNAbusiness.industrylcsh:RM1-950PyrosequencingMicroRNAmedicine.diseasepyrosequencinglcsh:Therapeutics. Pharmacology030104 developmental biologyMechanism of actionImmunologymedicine.symptombusinessDysbiosisprobioticFrontiers in Pharmacology
researchProduct

Impact of Oat-Based Products on Human Gastrointestinal Tract

2015

Abstract Oat is rich in valuable nutrients. In comparison to other cereals, oat contains more total proteins, carbohydrate, fat, non-starch fibre, as well as unique antioxidants (one of them - avenanthramides), vitamins, and minerals. One of the most often studied components of oats is β-glucan - a type of soluble dietary fibre located throughout the starch endosperm, but with highest concentration in the bran. Many studies have shown the beneficial health effects of oat β-glucan as a soluble dietary fibre. Until now, most of the studies on this nutrient have been conducted in the cardiovascular and diabetology field. This article aimed to review the literature on studies that investigated …

irritable bowel syndromemedicine.medical_specialtyMultidisciplinaryBranColorectal canceravena sativaScienceQHuman gastrointestinal tractfood and beveragesgastrointestinal microfloracolorectal cancermedicine.diseaseInflammatory bowel diseaseUlcerative colitisGastroenterologymedicine.anatomical_structureNutrientinflammatory bowel diseaseInternal medicinemedicineIn patientIrritable bowel syndromeProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

B lymphocyte intestinal homing in inflammatory bowel disease.

2011

Abstract Background Inflammatory bowel disease (IBD) is thought to be due to an abnormal interaction between the host immune system and commensal microflora. Within the intestinal immune system, B cells produce physiologically natural antibodies but pathologically atypical anti-neutrophil antibodies (xANCAs) are frequently observed in patients with IBD. The objective is to investigate the localisation of immunoglobulin-producing cells (IPCs) in samples of inflamed intestinal tissue taken from patients with IBD, and their possible relationship with clinical features. Methods The IPCs in small intestinal, colonic and rectal biopsy specimens of patients with IBD were analysed by means of immun…

lcsh:Immunologic diseases. AllergylymphocytesAdultMalePathologymedicine.medical_specialtyLymphocyteBiopsyImmunologyFluorescent Antibody TechniqueInflammatory bowel diseaseImmunophenotypingImmunomodulationImmune systemAntigens CDCell Movementinflammatory bowel diseasemedicineHumansB1 cells; Inflammation; Inflammatory bowel disease; Lymphocyte homing; Lymphocytes; Mucosal immunity; Adult; Aged; Antigens CD; B-Lymphocytes; Biopsy; Cell Differentiation; Cell Movement; Female; Fluorescent Antibody Technique; Humans; Immunoglobulin M; Immunomodulation; Immunophenotyping; Inflammatory Bowel Diseases; Intestinal Mucosa; Intestines; Male; Middle Aged; ImmunologyIntestinal MucosaB cellAgedB-LymphocytesbiologyB1 cellsCell DifferentiationMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesUlcerative colitisB-1 cellIntestinesmedicine.anatomical_structureImmunoglobulin MinflammationImmunologybiology.proteinmucosal immunityFemalelymphocyte homingCD5Antibodylcsh:RC581-607Research Article
researchProduct